Choice Mutual Fund Announces NFO for Large & Mid Cap Fund from October 20, 2026

Choice Mutual Fund Announces NFO for Large & Mid Cap Fund from October 20, 2026
Published on October 17, 2026|Author: Joshua Gaikwad
add us as a preferred source on google

add us as a preferred
source on google

“The fund will follow a Direct-Growth option and benchmark its performance against the NIFTY LargeMidcap 250 TRI.”

Choice Large & Mid Cap Fund NFO to Open on October 20, 2026

The Choice Large & Mid Cap Fund is designed for investors seeking long-term capital appreciation through investments in large-cap and mid-cap stocks. The scheme will be actively managed, with investments selected based on the fund’s investment strategy and market outlook.

The fund aims to build a portfolio of established companies and businesses with potential for future growth. However, returns are subject to market risks, and the scheme does not guarantee capital appreciation.

NFO Details and Investment Requirements

  • NFO Period: October 20 to November 3, 2026
  • Scheme Category: Large & Mid Cap Fund
  • Option: Direct-Growth
  • Benchmark: NIFTY LargeMidcap 250 TRI
  • Minimum Investment: Rs. 1,000 and in multiples of Rs. 1 thereafter
  • Minimum Additional Purchase: Rs. 1,000 and in multiples of Rs. 1 thereafter
  • Minimum SIP Amount: Rs. 500 and in multiples of Rs. 1, subject to a minimum of 12 instalments
  • Exit Load: 1% if units are redeemed or switched out before 365 days from allotment; the remaining terms should be checked in the scheme documents.
  • ISIN: INF2KCX01103

Investors can refer to the Scheme Information Document (SID) and Key Information Memorandum (KIM) for complete details about the fund, its terms and associated risks.

Investment Objective and Strategy

The fund aims to generate long-term capital appreciation through a portfolio of equity and equity-related instruments of large-cap and mid-cap companies. Its strategy focuses on identifying businesses with strong fundamentals, growth opportunities and competitive advantages.

As an actively managed scheme, the fund manager will select investments based on the scheme’s objectives and market conditions. The allocation between large-cap and mid-cap stocks may influence the fund’s risk and return profile.

Risk Factors to Consider

The Choice Large & Mid Cap Fund carries market-related risks because it invests in equities. Large-cap stocks may offer exposure to relatively established businesses, while mid-cap stocks can have different growth prospects and volatility levels.

Investors should review the scheme’s Risk-o-Meter and other disclosures before investing. The fund may be suitable for investors with a long-term investment horizon who understand equity market fluctuations and can tolerate potential losses.

What to Watch Next

Investors may want to review the fund’s complete scheme documents, portfolio strategy and risk disclosures before applying during the NFO period. The fund’s performance after launch will depend on market conditions, stock selection and the performance of its underlying investments.

Disclaimer

Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors. Choice Equity Broking Private Limited: SEBI Reg No. Broking - INZ000160131 ( BSE - 3299 ) | ( NSE - 13773 ) | ( MSEI - 73200 ) | ( MCX - 40585 ) | ( NCDEX - 01006 ). Depository Participant SEBI Reg. No. - IN - DP - 84 - 2015, DP ID CDSL - 12066900, NSDL ID - IN301895. Research Analyst - INH000000222 (CIN. NO.: U65999MH2010PTC198714)

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations

Other News

HDFC Mutual Fund Sells 2.027% Stake in Piramal Pharma

HDFC Mutual Fund Sells 2.027% Stake in Piramal Pharma

HDFC Mutual Fund has reduced its shareholding in Piramal Pharma Limited by selling 2,69,92,907 equity shares through the open market. The transaction represents a 2.027% stake in the company and was executed on October 28, 2026. Following the sale, HDFC Mutual Fund’s aggregate shareholding in Piramal Pharma declined from 7.015% to 4.988%. The disclosure was made by HDFC Asset Management Company Limited under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Mirae Asset Mutual Fund Sells 0.98% Stake in TeamLease Services

Mirae Asset Mutual Fund Sells 0.98% Stake in TeamLease Services

Mirae Asset Mutual Fund has sold 1,49,729 shares of TeamLease Services Limited through an open market transaction, reducing its stake in the company from 6.38% to 5.40%. Following the sale, the fund holds 8,25,414 shares in the staffing and human resource services company. The transaction was disclosed in a regulatory filing dated October 27, 2026.

SBI Mutual Fund Acquires 5.25% Stake in ASM Technologies

SBI Mutual Fund Acquires 5.25% Stake in ASM Technologies

SBI Mutual Fund has acquired a 5.25% stake in ASM Technologies Limited through a preferential allotment of equity shares. SBI Mutual Fund acquired 8,22,564 equity shares of the company, which were allotted on October 16, 2026. Following the allotment, its shareholding in ASM Technologies increased to 5.2501% of the company's paid-up share capital. The acquisition was made across various schemes of SBI Mutual Fund. The disclosure was submitted by SBI Funds Management Limited under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.